The Value Signal — October 15, 2026

628 articles scanned · 11 high-signal

Signal Map

Executive Summary

Washington and the payers are rewriting who gets paid, who gets waved through, and who keeps coverage, and the headline numbers mask far sharper movement underneath.

Star Ratings dominate the quality conversation. Healthcare Brew reports that the 2027 Medicare Advantage results triggered stock jumps and a lawsuit, and it also tracks a quieter shift toward value-based pharmacy agreements that tie reimbursement to quality metrics rather than volume. Wakely's analysis directly challenges the official narrative: CMS points to stable enrollment in bonus-eligible plans, but the firm finds "stability at the surface, volatility underneath," so plan-level exposure may be badly misread. Fee-for-service quality programs face a harsher verdict. Medical Economics reports MedPAC's finding that MIPS imposes big burdens on physicians in exchange for tiny bonuses and little value for patients, which adds weight to calls for structural reform.

On utilization management and program integrity, Healthcare Dive reports that Centene has joined insurers waiving prior authorizations for top providers through a gold card program as states and the Trump administration push for reform. The same administration has removed 189,000 deceased and duplicate enrollees from ACA subsidies as part of its "fraud, waste and abuse" crackdown. That enforcement posture carries coverage risk in Medicaid. KFF finds that Medicaid covered more than 1 in 4 SSDI applicants and beneficiaries waiting for Medicare (120,300 of 415,300 in 2023), a population that work requirements could leave struggling to keep coverage. In home-based and primary care, Home Health Care News reports that UnitedHealth is touting a 10% increase in Optum's home health visits. It also examines what Humana's BlackRock deal and Village Medical's divestitures signal for the economics of older-adult primary care, a sign of continued capital reshuffling around the senior care model.